These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 32777606)

  • 21. Patients' perspectives on initiating treatment with extended-release naltrexone (XR-NTX).
    Gauthier P; Greco P; Meyers-Ohki S; Desai A; Rotrosen J
    J Subst Abuse Treat; 2021 Mar; 122():108183. PubMed ID: 33162260
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cocaine use reduction with buprenorphine (CURB): rationale, design, and methodology.
    Mooney LJ; Nielsen S; Saxon A; Hillhouse M; Thomas C; Hasson A; Stablein D; McCormack J; Lindblad R; Ling W
    Contemp Clin Trials; 2013 Mar; 34(2):196-204. PubMed ID: 23159524
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized comparison of extended-release naltrexone with or without patient navigation vs enhanced treatment-as-usual for incarcerated adults with opioid use disorder.
    Farabee D; Condon T; Hallgren KA; McCrady B
    J Subst Abuse Treat; 2020 Oct; 117():108076. PubMed ID: 32811623
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical and psychosocial outcomes by sex among individuals prescribed buprenorphine-naloxone (BUP-NX) or extended-release naltrexone (XR-NTX) for opioid use disorder.
    Paschen-Wolff M; Greenfield SF; Kathryn McHugh R; Burlew K; Pavlicova M; Choo TH; Barbosa-Leiker C; Ruglass LM; Mennenga S; Rotrosen J; Nunes EV; Campbell ANC
    Am J Addict; 2023 Nov; 32(6):584-592. PubMed ID: 37583120
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of an injectable monthly extended-release buprenorphine program in a low-barrier specialty addiction medicine clinic.
    Heil J; Salzman M; Hunter K; Baston KE; Milburn C; Schmidt R; Haroz R; Ganetsky VS
    J Subst Use Addict Treat; 2024 Jan; 156():209183. PubMed ID: 37879433
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Health and economic outcomes of treatment with extended-release naltrexone among pre-release prisoners with opioid use disorder (HOPPER): protocol for an evaluation of two randomized effectiveness trials.
    Murphy SM; Jeng PJ; Poole SA; Jalali A; Vocci FJ; Gordon MS; Woody GE; Polsky D
    Addict Sci Clin Pract; 2020 Apr; 15(1):15. PubMed ID: 32321570
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Baseline- and treatment-associated pain in the X:BOT comparative effectiveness study of extended-release naltrexone versus buprenorphine-naloxone for OUD.
    Wang AL; Shulman M; Choo TH; Pavlicova M; Langleben DD; Nunes EV; Rotrosen J
    Addict Biol; 2022 Mar; 27(2):e13112. PubMed ID: 34877769
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association between methadone or buprenorphine use during medically supervised opioid withdrawal and extended-release injectable naltrexone induction failure.
    Shulman M; Choo TH; Scodes J; Pavlicova M; Wai J; Haenlein P; Tofighi B; Campbell ANC; Lee JD; Rotrosen J; Nunes EV
    J Subst Abuse Treat; 2021 May; 124():108292. PubMed ID: 33771287
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Surmounting Withdrawal to Initiate Fast Treatment with Naltrexone (SWIFT): A stepped wedge hybrid type 1 effectiveness-implementation study.
    Greiner MG; Shulman M; Opara O; Potter K; Voronca DC; Tafessu HM; Hefner K; Hamilton A; Scheele C; Ho R; Dresser L; Jelstrom E; Fishman M; Ghitza UE; Rotrosen J; Nunes EV; Bisaga A
    Contemp Clin Trials; 2023 May; 128():107148. PubMed ID: 36931426
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 'Not at all what I had expected': Discontinuing treatment with extended-release naltrexone (XR-NTX): A qualitative study.
    Brenna IH; Marciuch A; Birkeland B; Veseth M; Røstad B; Løberg EM; Solli KK; Tanum L; Weimand B
    J Subst Abuse Treat; 2022 May; 136():108667. PubMed ID: 34865937
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparing outcomes of extended-release naltrexone in adolescents and young adults with opioid use disorder.
    Mitchell SG; Fletcher JB; Monico LB; Gryczynski J; Fishman MJ; O'Grady KE; Schwartz RP
    J Subst Use Addict Treat; 2024 Aug; 163():209162. PubMed ID: 37730015
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patient Characteristics Associated with Opioid Abstinence after Participation in a Trial of Buprenorphine versus Injectable Naltrexone.
    Greiner MG; Shulman M; Scodes J; Choo TH; Pavlicova M; Opara O; Campbell ANC; Novo P; Fishman M; Lee JD; Rotrosen J; Nunes EV
    Subst Use Misuse; 2022; 57(11):1732-1742. PubMed ID: 35975917
    [No Abstract]   [Full Text] [Related]  

  • 33. Variants of opioid genes and response to treatment of opioid use disorder with buprenorphine-naloxone versus extended-release naltrexone in Caucasians.
    Randesi M; Rotrosen J; Nunes EV; Lee JD; Novo P; Levran O; Ott J; Pavlicova M; Scodes J; Kreek MJ
    Am J Drug Alcohol Abuse; 2020 Nov; 46(6):761-768. PubMed ID: 32851876
    [No Abstract]   [Full Text] [Related]  

  • 34. Continued Posttrial Benefits of Buprenorphine Extended Release: RECOVER Study Findings.
    Boyett B; Nadipelli VR; Solem CT; Chilcoat H; Bickel WK; Ling W
    J Addict Med; 2023 Mar-Apr 01; 17(2):182-189. PubMed ID: 36111991
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
    Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
    Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Explaining differential effects of medication for opioid use disorder using a novel approach incorporating mediating variables.
    Rudolph KE; Díaz I; Hejazi NS; van der Laan MJ; Luo SX; Shulman M; Campbell A; Rotrosen J; Nunes EV
    Addiction; 2021 Aug; 116(8):2094-2103. PubMed ID: 33340181
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Open-label, rapid initiation pilot study for extended-release buprenorphine subcutaneous injection.
    Hassman H; Strafford S; Shinde SN; Heath A; Boyett B; Dobbins RL
    Am J Drug Alcohol Abuse; 2023 Jan; 49(1):43-52. PubMed ID: 36001871
    [No Abstract]   [Full Text] [Related]  

  • 38. Revisiting the X:BOT Naltrexone Clinical Trial Using a Comprehensive Survival Analysis.
    Ajazi EM; Dasgupta N; Marshall SW; Monaco J; Howard AG; Preisser JS; Schwartz TA
    J Addict Med; 2022 Jul-Aug 01; 16(4):440-446. PubMed ID: 35960214
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of naltrexone implant and oral buprenorphine-naloxone in the treatment of opiate use disorder.
    Erdoğan A; Topcuoğlu M; Coşkun MN; Cinemre B; Kulaksızoğlu B; Kuloğlu MM
    Hum Psychopharmacol; 2022 Mar; 37(2):e2813. PubMed ID: 34532895
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Extended-release pharmacotherapy for opioid use disorder (EXPO): protocol for an open-label randomised controlled trial of the effectiveness and cost-effectiveness of injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone.
    Marsden J; Kelleher M; Hoare Z; Hughes D; Bisla J; Cape A; Cowden F; Day E; Dewhurst J; Evans R; Hearn A; Kelly J; Lowry N; McCusker M; Murphy C; Murray R; Myton T; Quarshie S; Scott G; Turner S; Vanderwaal R; Wareham A; Gilvarry E; Mitcheson L
    Trials; 2022 Aug; 23(1):697. PubMed ID: 35986418
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.